# CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

> **NCT05291156** · PHASE2 · UNKNOWN · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 173 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT05291156
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-21
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 173 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05291156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05291156, "CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05291156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*